U.S. Genome Editing Market Size & Outlook, 2024-2030
U.S. genome editing market, 2018-2030 (US$M)
Related Markets
U.S. genome editing market highlights
- The U.S. genome editing market generated a revenue of USD 3,498.1 million in 2023 and is expected to reach USD 10,689.8 million by 2030.
- The U.S. market is expected to grow at a CAGR of 17.3% from 2024 to 2030.
- In terms of segment, (crispr)/cas9 was the largest revenue generating technology in 2023.
- (CRISPR)/Cas9 is the most lucrative technology segment registering the fastest growth during the forecast period.
Genome editing market data book summary
| Market revenue in 2023 | USD 3,498.1 million |
| Market revenue in 2030 | USD 10,689.8 million |
| Growth rate | 17.3% (CAGR from 2023 to 2030) |
| Largest segment | (crispr)/cas9 |
| Fastest growing segment | (CRISPR)/Cas9 |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | (CRISPR)/Cas9, TALENs/MegaTALs, ZFN, Meganuclease |
| Key market players worldwide | Merck KGaA, Cibus Inc Ordinary Shares - Class A, Recombinetics, Sangamo Therapeutics Inc, Editas Medicine Inc, Precision BioSciences Inc, CRISPR Therapeutics AG, Intellia Therapeutics Inc, Caribou Biosciences Inc Ordinary Shares, Cellectis SA, AstraZeneca PLC, Takara Bio Inc, Horizon Discovery, Danaher Corp, Genscript Biotech Corp Class H, New England Biolabs, Origene Technologies, Bluebird bio Inc, Lonza Group Ltd, Thermo Fisher Scientific Inc |
Other key industry trends
- In terms of revenue, U.S. accounted for 43.9% of the global genome editing market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. genome editing market is projected to lead the regional market in terms of revenue in 2030.
- Canada is the fastest growing regional market in North America and is projected to reach USD 1,028.1 million by 2030.
(crispr)/cas9 was the largest segment with a revenue share of 41.8% in 2024. Horizon Databook has segmented the U.S. genome editing market based on (crispr)/cas9, talens/megatals, zfn, meganuclease covering the revenue growth of each sub-segment from 2018 to 2030.
The presence of robust research infrastructure, rise in genetically modified crops, and increase in prevalence of genetic diseases are some of the major driving factors boosting the U.S. genome editing market. Moreover, in the U.S., genetic diseases such as cystic fibrosis are prevalent.
According to the Cystic Fibrosis Foundation Patient Registry, around 30,000 people are suffering from cystic fibrosis in the country. On the other hand, rise in the number of patent approvals for U.S.-based companies has also accelerated the adoption of genome editing tools in the country, leading to positive market growth.
For instance, in May 2020, Merck announced that two CRISPR gene editing patents were approved in the U.S. In September 2020, Editas Medicine revealed that the U.S. Patent and Trademark Office approved certain Broad’s CRISPR/Cas9 patents for priority benefits. Such novel initiatives are expected to drive market growth in the country.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Genome Editing Market Scope
Genome Editing Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. genome editing market size, by technology, 2018-2030 (US$M)
U.S. Genome Editing Market Outlook Share, 2024 & 2030 (US$M)
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
